US2014242028A1PendingUtilityA1
Antiviral compounds
Est. expiryJan 23, 2033(~6.5 yrs left)· nominal 20-yr term from priority
Inventors:Joseph Anthony BilottaZhi ChenQingjie DingShawn David EricksonEric MertzRobert James Weikert
A61P 31/14A61P 1/16A61K 31/4439C07D 249/14C07D 401/12A61K 31/4196A61K 45/06
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
Claims
exact text as granted — not AI-modified1 . A compound of formula I
wherein:
R 1 is H or lower alkyl;
each R 2 is independently halo or lower haloalkyl;
n is 0, 1, or 2;
R 3 is lower haloalkyl, cyano, lower alkoxy, C(═O)OCH 3 , or S(═O) 2 CH 3 ;
p is 0, or 1;
X 1 is S, S(═O) 2 , O, S(═O), NH, or OCH 2 ; and
X 2 is CH or N;
or a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 , wherein X 2 is CH and R 1 is H.
3 . The compound of claim 2 , wherein X 1 is S or 0.
4 . The compound of claim 2 , wherein X 1 is S(═O) 2 or S(═O).
5 . The compound of any one of claim 1 , wherein n is 1.
6 . The compound of any one of claim 1 , wherein n is 2.
7 . The compound of claim 5 , wherein R 1 is Cl.
8 . The compound of claim 6 , wherein both R 1 are Cl.
9 . The compound of any one of claim 1 , wherein p is 0.
10 . The compound of any one of claim 1 , wherein p is 1.
11 . The compound of claim 10 , wherein R 3 is or S(═O) 2 CH 3 , cyano, or CF 3 .
12 . A compound selected from the group consisting of:
N5-(3-Fluoro-4-phenylsulfanyl-5-trifluoromethyl-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-(3-Chloro-4-phenylamine-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-(3-Chloro-4-phenoxy-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3(3,5-Dichloro-4-phenylsulfanyl-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3(4-Benzenesulfinyl-3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3(4-Benzenesulfinyl-3,5-dichloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N3-[3,5-Dichloro-4-(4-trifluoromethyl-phenylsulfanyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N3-[3,5-Dichloro-4-(4-trifluoromethyl-benzenesulfinyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N3-[3,5-Dichloro-4-(4-trifluoromethyl-benzenesulfinyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(2-trifluoromethyl-phenylsulfanyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4-(3-trifluoromethyl-benzenesulfinyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; 4-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2,6-dichloro-phenylsulfanyl]-benzonitrile; 4-[4(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2,6-dichloro-benzenesulfinyl]-benzonitrile; 4-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2,6-dichloro-benzenesulfonyl]-benzonitrile; 4-[4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-2-chloro-6-trifluoromethyl-phenylsulfanyl]-benzoic acid methyl ester; N 3 -[3,5-Dichloro-4-(4-methoxy-phenylsulfanyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3-Chloro-4-(4-methoxy-phenylsulfanyl)-5-trifluoromethyl-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3,5-Dichloro-4(4-methoxy-benzenesulfonyl)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3[ 3,5-Dichloro-4(4-methanesulfonyl-phenoxy)-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 -[3-Chloro-4-(4-methanesulfonyl-phenoxy)-5-tiifluoromethyl-phenyl]-1H-[1,2,4]triazole-3,5-diamine; N 3 (3-Benzyloxy-5-chloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -(3-Chloro-4-phenylsulfanyl-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -(4-Benzenesulfonyl-3-chloro-phenyl)-1H-[1,2,4]triazole-3,5-diamine; N 3 -(3-Chloro-4-phenylsulfanyl-phenyl)-N 3 -methyl-1H-[1,2,4]triazole-3,5-diamine; N 3 -(3-Chloro-5-phenoxy-phenyl)-1H-[1,2,4]triazole-3,5-diamine; and N 3 -[3,5-Dichloro-4-(pyridin-2-yloxy)-phenyl]-1H-[1,2,4]triazole-3,5-diamine.
13 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 .
14 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 2 .
15 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 3 .
16 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 4 .
17 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 5 .
18 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 6 .
19 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 7 .
20 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 8 .
21 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 9 .
22 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 10 .
23 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 11 .
24 . A method for preventing a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 12 .
25 . The method of claim 1 , further comprising administering to a patient in need thereof a therapeutically effective amount of an immune system suppressant.
26 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 .
27 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 2 .
28 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 3 .
29 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 4 .
30 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claim 5 .
31 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 6 .
32 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 6 .
33 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 7 .
34 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 8 .
35 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 9 .
36 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 10 .
37 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 11 .
38 . A method for treating a Hepatitis C Virus (HCV) infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 12 .
39 . The method of claim 1 , further comprising administering a combination of antiviral agents that inhibits replication of HCV.
40 . The method of claim 1 , further comprising administering an immune system modulator or an antiviral agent that inhibits replication of HCV, or a combination thereof.
41 . The method of claim 39 , wherein the immune system modulator is an interferon or a chemically derivatized interferon.
42 . The method of claim 38 , wherein the antiviral agent is selected from the group consisting of a HCV protease inhibitor, a HCV polymerase inhibitor, a HCV helicase inhibitor, a HCV NS5A inhibitor, or any combination thereof.
43 . A composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.Join the waitlist — get patent alerts
Track US2014242028A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.